NCT00894075View on ClinicalTrials.gov

Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

July 31, 2009

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Hypophosphatasia
Interventions
BIOLOGICAL

ENB-0040

1mg/kg subcutaneous injection thrice weekly for 6 months

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY